Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05563883
Active, not recruiting Observational

Atrial Fibrillation and Cancer: a Nationwide French Cohort Study

NCT05563883 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Caen
Phase
Observational
Started
2022-09-22
Last updated
2022-10-03

Condition(s) studied

Atrial FibrillationCancerThromboembolismBleeding

Investigational drug(s) / intervention(s)

event occurence

event occurence: occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...

Study summary

Atrial fibrillation (AF) is a common complication associated with cancer but the risk of AF according to the cancer localization and status as well as the risk of thromboembolisms, bleedings and mortality are poorly known.

The objective of this study is to use a very large French nationwide cohort to adress thèses questions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * adult hospitalized patients * with an ICD-10 code discharge from january 2010 to december 2019 in the French national hospital discharge database (PMSI Programme de Médicalisation des Systèmes d'Information) Exclusion Criteria: * children

Primary outcome measure(s)

  • atrial fibrillation — from inclusion in the cohort up to 10 years
    occurrence of atrial fibrillation
  • cancer — ffrom inclusion in the cohort up to 10 years
    occurrence of cancer

Trial sites (1)

FacilityCityRegionStatus
Service de Cardiologie, Centre Hospitalier Universitaire Trousseau Tours France

More University Hospital, Caen trials in France

NEUROIMAGING OF ADOLESCENT BORDERLINE PERSONALITY DISORDER WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER Recruiting
Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency Recruiting
Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs Recruiting
Longitudinal Monitoring of Head Impacts in Elite Junior Ice Hockey Active, not recruiting
An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care Recruiting

Other trials for the same condition

Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA Recruiting
Vulnerability and Risk of Neuropathic Pain in Cancer Recruiting
STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers Recruiting
Open Label Clinical Trial of Intravenous Crotoxin Part 3 Starting soon
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05563883 on ClinicalTrials.gov ↗ ← All trials in France